David Shprecher
A5054891890- Parkinson's Disease Mechanisms and Treatments
- Obsessive-Compulsive Spectrum Disorders
- Neurological disorders and treatments
- Autism Spectrum Disorder Research
- Ginkgo biloba and Cashew Applications
- Restless Legs Syndrome Research
- Dementia and Cognitive Impairment Research
- Botulinum Toxin and Related Neurological Disorders
- Sleep and Wakefulness Research
- Attention Deficit Hyperactivity Disorder
- Genetic Neurodegenerative Diseases
- Alzheimer's disease research and treatments
- Nuclear Receptors and Signaling
- Chemical Reactions and Isotopes
- Olfactory and Sensory Function Studies
- RNA regulation and disease
- Pharmacological Effects and Toxicity Studies
- Neuroinflammation and Neurodegeneration Mechanisms
- Sleep and related disorders
- Balance, Gait, and Falls Prevention
- Cerebral Palsy and Movement Disorders
- Long-Term Effects of COVID-19
- Neurological Disease Mechanisms and Treatments
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
Banner Sun Health Research Institute
2016-2025
University of Arizona
2017-2025
Banner Health
2021-2025
Banner - University Medical Center Tucson
2024
Centre National de la Recherche Scientifique
2024
Banner - University Medical Center Phoenix
2024
Université Clermont Auvergne
2024
Institut Pascal
2024
University of Rochester
2008-2022
University of Utah
2012-2021
<h3>Importance</h3> Deutetrabenazine is a novel molecule containing deuterium, which attenuates CYP2D6 metabolism and increases active metabolite half-lives may therefore lead to stable systemic exposure while preserving key pharmacological activity. <h3>Objective</h3> To evaluate efficacy safety of deutetrabenazine treatment control chorea associated with Huntington disease. <h3>Design, Setting, Participants</h3> Ninety ambulatory adults diagnosed manifest disease baseline total maximal...
To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD).One hundred seventeen patients with moderate to severe TD received or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score ≥6 assessed by blinded central video rating, stable psychiatric illness, psychoactive medication treatment. Primary endpoint was change AIMS from baseline week 12. Secondary endpoints...
Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, clinical data.To determine whether sustained urate-elevating treatment the urate precursor inosine slows early PD progression.Randomized, double-blind, placebo-controlled, phase 3 trial of oral in PD. A total 587 individuals consented, 298 not yet requiring...
Abstract Digital health technologies can provide continuous monitoring and objective, real-world measures of Parkinson’s disease (PD), but have primarily been evaluated in small, single-site studies. In this 12-month, multicenter observational study, we whether a smartwatch smartphone application could measure features early PD. 82 individuals with early, untreated PD 50 age-matched controls wore research-grade sensors, smartwatch, while performing standardized assessments the clinic. At...
Delayed post-hypoxic leukoencephalopathy (DPHL) is a demyelinating syndrome characterized by acute onset of neuropsychiatric symptoms days to weeks following apparent recovery from coma after period prolonged cerebral hypo-oxygenation. It dia
<h3>Objective:</h3> To identify an improved measure of clinical progression in early Huntington disease (HD) using data from prospective observational cohort studies and placebo group randomized double-blind trials. <h3>Methods:</h3> We studied Unified Disease Rating Scale (UHDRS) non-UHDRS measures brain progressive atrophy 1,668 individuals with HD followed up prospectively for to 30 36 months longitudinal follow-up. <h3>Results:</h3> The results demonstrated that a composite motor,...
To test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow progressive functional decline HD.We performed a multicenter randomized, double-blind, placebo-controlled trial. Patients HD (n = 609) were enrolled at 48 sites in United States, Canada, and Australia from 2008 to 2012. randomized receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was change baseline month...
To identify the causal gene in a multi-incident U.S. kindred with Parkinson's disease (PD). We characterized family classical PD phenotype which 7 individuals (5 males and 2 females) were affected mean age at onset of 46.1 years (range, 29-57 years). performed whole exome sequencing on 4 1 unaffected members. Sanger-sequencing was then used to verify genotype all candidate variants remainder pedigree. Cultured cells transfected wild-type or mutant constructs characterize proteins interest....
The coronavirus SARS-CoV-2 (SCV2) causes acute respiratory distress, termed COVID-19 disease, with substantial morbidity and mortality. As SCV2 is related to previously-studied coronaviruses that have been shown the capability for brain invasion, it seems likely may be able do so as well. To date, although there many clinical autopsy-based reports describe a broad range of SCV2-associated neurological conditions, unclear what fraction these due direct CNS invasion versus indirect effects...
Rapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created multisite participant, primarily clinic-based cohort better understand characteristics diagnosis, and in future work, identify predictors...
Digital measures may provide objective, sensitive, real-world of disease progression in Parkinson's (PD). However, multicenter longitudinal assessments such are few. We recently demonstrated that baseline gait, tremor, finger tapping, and speech from a commercially available smartwatch, smartphone, research-grade wearable sensors differed significantly between 82 individuals with early, untreated PD 50 age-matched controls. Here, we evaluated the change these over 12 months observational...
This study was designed to correlate clinical findings with the extent of pathologic a-synuclein (aSyn) in brain using Unified Staging System for Lewy Body disorders (USSLB). Data from 280 cases Arizona Study Aging and Neurodegenerative Disorders are presented. Each case had a complete USSLB staging at least 1 full research assessment, including subspecialty neurologist-administered movement cognitive evaluation. Of 280, 25.7% were cognitively normal, 8.6% mild impairment, 65.7% dementia....
The cause of progressive supranuclear palsy (PSP) is largely unknown. Based on evidence for impaired mitochondrial activity in PSP, we hypothesized that the disease may be related to exposure environmental toxins, some which are inhibitors.This multicenter case-control study included 284 incident PSP cases 350 and age-, sex-, race-matched controls primarily from same geographical areas. All subjects were administered standardized interviews obtain data demographics, residential history,...
<strong>Background:</strong> Deutetrabenazine, an inhibitor of vesicular monoamine transporter type 2 (VMAT2) depletes presynaptic dopamine and is useful in the treatment hyperkinetic movement disorders. This study explored safety, tolerability, preliminary efficacy deutetrabenazine adolescents with moderate-to-severe tics associated Tourette syndrome (TS). <strong>Methods:</strong> In this open-label 12–18-year-old patients TS-related tics, was titrated up to 36 mg/day over 6 weeks...
Brains of 42 COVID-19 decedents and 107 non-COVID-19 controls were studied. RT-PCR screening 16 regions from 20 autopsies found SARS-CoV-2 E gene viral sequences in 7 (2.5% 320 samples), concentrated 4/20 subjects (20%). Additional olfactory bulb (OB), amygdala (AMY) entorhinal area for E, N1, N2, RNA-dependent RNA polymerase, S detected one or more these OB 8/21 (38%). It is uncertain whether represent viable virus. Significant histopathology was limited to 2/42 cases (4.8%), with a large...
Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label study patients PD.To evaluate safety efficacy oral for neurologic symptoms PD constipation.Randomized, placebo-controlled phase 2b study. (ClinicalTrials.gov: NCT03781791).Outpatient.150 constipation.ENT-01 or placebo daily up to 25 days. After baseline assessment severity, dosing was escalated prokinetic...
REM sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment. The International RBD Study Group developed the Symptom Severity Scale (RBDSSS) to assess symptom severity for clinical or research use. We assessed psychometric and clinimetric properties of RBDSSS in participants enrolled North American Prodromal Synucleinopathy (NAPS) Consortium RBD. NAPS participants, who have polysomnogram-confirmed RBD, their bedpartners completed (participant bedpartner versions)....
Neuropathology has demonstrated a high rate of comorbid pathology in dementia due to Alzheimer's disease (ADD). The most common major comorbidity is Lewy body (LBD), either as with bodies (AD-DLB) or (AD-LB), the latter representing subjects ADD and LBD not meeting neuropathological distribution density thresholds for DLB. Although it been established that undifferentiated have more rapid cognitive decline than those alone, still unknown whether AD-LB subjects, who represent majority...